Siemens Biomarker Multi-modality
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorDuke University
About this trial
The purpose of this study is to see how well Photon Counting CT (PCCT) and ultrasound test results can find fat and scarring in the liver. They will be compared to MRI test results as the reference standard. Participants will get a regular CT scan on the PCCT scanner, plus a few extra pictures just for the study. They will also get an MRI, either on the same day or a different day, whichever is preferred. Participants will get an ultrasound on the same day as the MRI. If they have not had a hematocrit blood test in the past 24 hours, they will also receive one on the day of the CT scan.
Eligibility criteria
Qualifiers
Age of 18 years or older
Has clinically indicated CT schedule including the liver (with contrast or with and without contrast)
Patient eligible for MR imaging
History of chronic diffuse liver disease, steatotic liver disease, and/ or liver fibrosis
Disqualifiers
Contraindications to any of the required imaging examinations
BMI > 45 (based on MRI scanner capacity)
Trial design
Treatments tested in this trial
- Photon-counting CT (PCCT)
- Ultrasound
- Magnetic Resonance Imaging (MRI)
Treatment groups
45 Participants
are divided into 3 treatment groupsLocations
1Duke University Medical Center27710, DurhamNorth Carolina, United States
Sponsors and collaborators
Duke University
Lead sponsor
Siemens Healthineers AG
Collaborator
Source ClinicalTrials.gov